Desipramine decreases expression of human and murine indoleamine-2,3-dioxygenases

Brain, Behavior, and Immunity

Volumn 62, Issue , 2017, Pages 219-229

  Brooks, Alexandra K ^a   Janda, Tiffany M ^a   Lawson, Marcus A ^a   Rytych, Jennifer L ^a   Smith, Robin A ^a   Ocampo Solis, Cecilia ^a   McCusker, Robert H ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Depression; Desipramine; Ido1; Inflammation; Kynurenine pathway; PBMCs

Indexed keywords

BIOLOGICAL MARKER; DESIPRAMINE; DEXAMETHASONE; GAMMA INTERFERON; IDO1 PROTEIN; IDO2 PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG; ADRENERGIC RECEPTOR AFFECTING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; DRUG ACTIVITY; HIPPOCAMPUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; MICROGLIA; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; STRESS; ANIMAL; DRUG EFFECT; FEMALE; GENETICS; MALE; METABOLISM; MONONUCLEAR CELL; YOUNG ADULT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; DESIPRAMINE; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALE; MICE; YOUNG ADULT;

EID: 85013414505     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2017.02.010     Document Type: Article

References (97)

1. Albuquerque, E.X., Schwarcz, R., Kynurenic acid as an antagonist of alpha7 nicotinic acetylcholine receptors in the brain: facts and challenges. Biochem. Pharmacol. 85 (2013), 1027–1032.
2. Anderson, I.M., SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 7:Suppl. 1 (1998), 11–17.
3. Ball, H.J., Yuasa, H.J., Austin, C.J., Weiser, S., Hunt, N.H., Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int. J. Biochem. Cell Biol. 41 (2009), 467–471.
4. Baranyi, A., Meinitzer, A., Breitenecker, R.J., Amouzadeh-Ghadikolai, O., Stauber, R., Rothenhausler, H.B., Quinolinic acid responses during interferon-alpha-induced depressive symptomatology in patients with chronic hepatitis C infection – a novel aspect for depression and inflammatory hypothesis. PLoS One, 10, 2015, e0137022.
5. Basu Mallik, S., Mudgal, J., Nampoothiri, M., Hall, S., Dukie, S.A., Grant, G., Rao, C.M., Arora, D., Caffeic acid attenuates lipopolysaccharide-induced sickness behaviour and neuroinflammation in mice. Neurosci. Lett. 632 (2016), 218–223.
6. Braidy, N., Rossez, H., Lim, C.K., Jugder, B.E., Brew, B.J., Guillemin, G.J., Characterization of the kynurenine pathway in CD8+ human primary monocyte-derived dendritic cells. Neurotox. Res., 2016.
7. Branco-de-Almeida, L.S., Kajiya, M., Cardoso, C.R., Silva, M.J., Ohta, K., Rosalen, P.L., Franco, G.C., Han, X., Taubman, M.A., Kawai, T., Selective serotonin reuptake inhibitors attenuate the antigen presentation from dendritic cells to effector T lymphocytes. FEMS Immunol. Med. Microbiol. 62 (2011), 283–294.
8. Brooks, A.K., Lawson, M.A., Rytych, J.L., Yu, K.C., Janda, T.M., Steelman, A.J., McCusker, R.H., Immunomodulatory factors galectin-9 and interferon-gamma synergize to induce expression of rate-limiting enzymes of the kynurenine pathway in the mouse hippocampus. Front. Immunol., 7, 2016.
9. Brooks, A.K., Lawson, M.A., Smith, R.A., Janda, T.M., Kelley, K.W., McCusker, R.H., Interactions between inflammatory mediators and corticosteroids regulate transcription of genes within the Kynurenine Pathway in the mouse hippocampus. J. Neuroinflamm., 13, 2016, 98.
10. Browne, C.A., O'Brien, F.E., Connor, T.J., Dinan, T.G., Cryan, J.F., Differential lipopolysaccharide-induced immune alterations in the hippocampus of two mouse strains: effects of stress. Neuroscience 225 (2012), 237–248.
11. Capuron, L., Ravaud, A., Neveu, P.J., Miller, A.H., Maes, M., Dantzer, R., Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol. Psychiatry 7 (2002), 468–473.
12. Carvalho, F.B., Gutierres, J.M., Bueno, A., Agostinho, P., Zago, A.M., Vieira, J., Fruhauf, P., Cechella, J.L., Nogueira, C.W., Oliveira, S.M., Rizzi, C., Spanevello, R.M., Duarte, M.M., Duarte, T., Dellagostin, O.A., Andrade, C.M., Anthocyanins control neuroinflammation and consequent memory dysfunction in mice exposed to lipopolysaccharide. Mol. Neurobiol., 2016.
13. Cobb, J.A., O'Neill, K., Milner, J., Mahajan, G.J., Lawrence, T.J., May, W.L., Miguel-Hidalgo, J., Rajkowska, G., Stockmeier, C.A., Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder. Neuroscience 316 (2016), 209–220.
14. Constant, A., Castera, L., Dantzer, R., Couzigou, P., de Ledinghen, V., Demotes-Mainard, J., Henry, C., Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J. Clin. Psychiatry 66 (2005), 1050–1057.
15. Corona, A.W., Norden, D.M., Skendelas, J.P., Huang, Y., O'Connor, J.C., Lawson, M., Dantzer, R., Kelley, K.W., Godbout, J.P., Indoleamine 2,3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activation and depressive-like complications in fractalkine receptor (CX(3)CR1)-deficient mice. Brain Behav. Immun. 31 (2013), 134–142.
16. Croitoru-Lamoury, J., Lamoury, F.M., Caristo, M., Suzuki, K., Walker, D., Takikawa, O., Taylor, R., Brew, B.J., Interferon-gamma regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO). PLoS One, 6, 2011, e14698.
17. Czeh, B., Di Benedetto, B., Antidepressants act directly on astrocytes: evidences and functional consequences. Eur. Neuropsychopharmacol. 23 (2013), 171–185.
18. Dantzer, R., Kelley, K.W., Twenty years of research on cytokine-induced sickness behavior. Brain Behav. Immun. 21 (2007), 153–160.
19. Dantzer, R., Wollman, E.E., Vitkovic, L., Yirmiya, R., Cytokines, stress, and depression. Conclusions and perspectives. Adv. Exp. Med. Biol. 461 (1999), 317–329.
20. Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9 (2008), 46–56.
21. Dantzer, R., O'Connor, J.C., Lawson, M.A., Kelley, K.W., Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 36 (2011), 426–436.
22. Diamond, M., Kelly, J.P., Connor, T.J., Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur. Neuropsychopharmacol. 16 (2006), 481–490.
23. Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctot, K.L., A meta-analysis of cytokines in major depression. Biol. Psychiatry 67 (2010), 446–457.
24. Duseja, R., Heir, R., Lewitus, G.M., Altimimi, H.F., Stellwagen, D., Astrocytic TNFalpha regulates the behavioral response to antidepressants. Brain Behav. Immun. 44 (2015), 187–194.
25. Elgarf, A.S., Aboul-Fotouh, S., Abd-Alkhalek, H.A., El Tabbal, M., Hassan, A.N., Kassim, S.K., Hammouda, G.A., Farrag, K.A., Abdel-tawab, A.M., Lipopolysaccharide repeated challenge followed by chronic mild stress protocol introduces a combined model of depression in rats: reversibility by imipramine and pentoxifylline. Pharmacol. Biochem. Behav. 126 (2014), 152–162.
26. Fatokun, A.A., Hunt, N.H., Ball, H.J., Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease. Amino Acids 45 (2013), 1319–1329.
27. Feldmann, M., Pathipati, P., Sheldon, R.A., Jiang, X., Ferriero, D.M., Isolating astrocytes and neurons sequentially from postnatal murine brains with a magnetic cell separation technique. J. Biol. Methods, 1, 2014, 11.
28. Fukunaga, M., Yamamoto, Y., Kawasoe, M., Arioka, Y., Murakami, Y., Hoshi, M., Saito, K., Studies on tissue and cellular distribution of indoleamine 2,3-dioxygenase 2: the absence of IDO1 upregulates IDO2 expression in the epididymis. J. Histochem. Cytochem. 60 (2012), 854–860.
29. Galecki, P., Galecka, E., Maes, M., Chamielec, M., Orzechowska, A., Bobinska, K., Lewinski, A., Szemraj, J., The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. J. Affect. Disord. 138 (2012), 360–366.
30. Gibney, S.M., McGuinness, B., Prendergast, C., Harkin, A., Connor, T.J., Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain Behav. Immun. 28 (2013), 170–181.
31. Gonzalez-Pena, D., Nixon, S.E., O'Connor, J.C., Southey, B.R., Lawson, M.A., McCusker, R.H., Borras, T., Machuca, D., Hernandez, A.G., Dantzer, R., Kelley, K.W., Rodriguez-Zas, S.L., Microglia transcriptome changes in a model of depressive behavior after immune challenge. PLoS One, 11, 2016, e0150858.
32. Guillemin, G.J., Quinolinic acid, the inescapable neurotoxin. FEBS J. 279 (2012), 1356–1365.
33. Guillemin, G.J., Kerr, S.J., Smythe, G.A., Smith, D.G., Kapoor, V., Armati, P.J., Croitoru, J., Brew, B.J., Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J. Neurochem. 78 (2001), 842–853.
34. Guillemin, G.J., Smythe, G., Takikawa, O., Brew, B.J., Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49 (2005), 15–23.
35. Haeryfar, S.M., Hoskin, D.W., Thy-1: more than a mouse pan-T cell marker. J. Immunol. 173 (2004), 3581–3588.
36. Hilmas, C., Pereira, E.F., Alkondon, M., Rassoulpour, A., Schwarcz, R., Albuquerque, E.X., The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 21 (2001), 7463–7473.
37. Holt, L.M., Olsen, M.L., Novel applications of magnetic cell sorting to analyze cell-type specific gene and protein expression in the central nervous system. PLoS One, 11, 2016, e0150290.
38. Hoyo-Becerra, C., Schlaak, J.F., Hermann, D.M., Insights from interferon-alpha-related depression for the pathogenesis of depression associated with inflammation. Brain Behav. Immun. 42 (2014), 222–231.
39. Hughes, M.M., Connor, T.J., Harkin, A., Stress-related immune markers in depression: implications for treatment. Int. J. Neuropsychopharmacol., 2016.
40. Jain, N.K., Kulkarni, S.K., Singh, A., Lipopolysaccharide-mediated immobility in mice: reversal by cyclooxygenase enzyme inhibitors. Methods Find. Exp. Clin. Pharmacol. 23 (2001), 441–444.
41. Jakubovski, E., Varigonda, A.L., Freemantle, N., Taylor, M.J., Bloch, M.H., Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. Am. J. Psychiatry 173 (2016), 174–183.
42. Jeong, H.K., Jou, I., Joe, E.H., Systemic LPS administration induces brain inflammation but not dopaminergic neuronal death in the substantia nigra. Exp. Mol. Med. 42 (2010), 823–832.
43. John, S., Mishra, R., Galectin-9: from cell biology to complex disease dynamics. J. Biosci. 41 (2016), 507–534.
44. Jones, S.P., Franco, N.F., Varney, B., Sundaram, G., Brown, D.A., de Bie, J., Lim, C.K., Guillemin, G.J., Brew, B.J., Expression of the kynurenine pathway in human peripheral blood mononuclear cells: implications for inflammatory and neurodegenerative disease. PLoS One, 10, 2015, e0131389.
45. Jungblut, M., Tiveron, M.C., Barral, S., Abrahamsen, B., Knobel, S., Pennartz, S., Schmitz, J., Perraut, M., Pfrieger, F.W., Stoffel, W., Cremer, H., Bosio, A., Isolation and characterization of living primary astroglial cells using the new GLAST-specific monoclonal antibody ACSA-1. Glia 60 (2012), 894–907.
46. Kai, S., Goto, S., Tahara, K., Sasaki, A., Tone, S., Kitano, S., Indoleamine 2,3-dioxygenase is necessary for cytolytic activity of natural killer cells. Scand. J. Immunol. 59 (2004), 177–182.
47. Kantor, E.D., Rehm, C.D., Haas, J.S., Chan, A.T., Giovannucci, E.L., Trends in prescription drug use among adults in the United States from 1999–2012. JAMA 314 (2015), 1818–1831.
48. Kappelmann, N., Lewis, G., Dantzer, R., Jones, P.B., Khandaker, G.M., Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol. Psychiatry, 2016.
49. Kim, H., Chen, L., Lim, G., Sung, B., Wang, S., McCabe, M.F., Rusanescu, G., Yang, L., Tian, Y., Mao, J., Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J. Clin. Invest. 122 (2012), 2940–2954.
50. Kirsch, I., Sapirstein, G., Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevent. Treatment 1 (1998), 1–16.
51. Kwidzinski, E., Bunse, J., Kovac, A.D., Ullrich, O., Zipp, F., Nitsch, R., Bechmann, I., IDO (indolamine 2,3-dioxygenase) expression and function in the CNS. Adv. Exp. Med. Biol. 527 (2003), 113–118.
52. Kwidzinski, E., Bunse, J., Aktas, O., Richter, D., Mutlu, L., Zipp, F., Nitsch, R., Bechmann, I., Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J. 19 (2005), 1347–1349.
53. Lawson, M.A., Parrott, J.M., McCusker, R.H., Dantzer, R., Kelley, K.W., O'Connor, J.C., Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2,3-dioxygenase-dependent depression-like behaviors. J. Neuroinflamm., 10, 2013, 87.
54. Lawson, M.A., Dostal, C.R., Brooks, A.K., McCusker, R.H., The Kynurenine (Kyn) pathway and neuroinflammation: the confused brain. Opp, M.R., (eds.) Primer of PsychoNeuroImmunology Research, 2016, PsychoNeuroImmunology Research Society, Los Angeles, CA, 95–101.
55. Lee, Y.K., Lee, H.B., Shin, D.M., Kang, M.J., Yi, E.C., Noh, S., Lee, J., Lee, C., Min, C.K., Choi, E.Y., Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2. Exp. Mol. Med., 46, 2014, e121.
56. Lippens, C., Duraes, F.V., Dubrot, J., Brighouse, D., Lacroix, M., Irla, M., Aubry-Lachainaye, J.P., Reith, W., Mandl, J.N., Hugues, S., IDO-orchestrated crosstalk between pDCs and Tregs inhibits autoimmunity. J. Autoimmun., 2016.
57. Liu, F.T., Rabinovich, G.A., Galectins: regulators of acute and chronic inflammation. Ann. N. Y. Acad. Sci. 1183 (2010), 158–182.
58. Liu, Y.N., Peng, Y.L., Liu, L., Wu, T.Y., Zhang, Y., Lian, Y.J., Yang, Y.Y., Kelley, K.W., Jiang, C.L., Wang, Y.X., TNFalpha mediates stress-induced depression by upregulating indoleamine 2,3-dioxygenase in a mouse model of unpredictable chronic mild stress. Eur. Cytokine Netw. 26 (2015), 15–25.
59. Lutomski, D., Joubert-Caron, R., Lefebure, C., Salama, J., Belin, C., Bladier, D., Caron, M., Anti-galectin-1 autoantibodies in serum of patients with neurological diseases. Clin. Chim. Acta 262 (1997), 131–138.
60. Maldonado, R.A., von Andrian, U.H., How tolerogenic dendritic cells induce regulatory T cells. Adv. Immunol. 108 (2010), 111–165.
61. Marcus, M., Yasamy, M.T., van Ommeren, M., Chisholm, D., Saxena, S., Depression A Global Health Concern. 2012, World Health Organization Department of Mental Health and Substance Abuse, 1–8.
62. Matt, S.M., Lawson, M.A., Johnson, R.W., Aging and peripheral lipopolysaccharide can modulate epigenetic regulators and decrease IL-1beta promoter DNA methylation in microglia. Neurobiol. Aging 47 (2016), 1–9.
63. Mello, B.S., Monte, A.S., McIntyre, R.S., Soczynska, J.K., Custodio, C.S., Cordeiro, R.C., Chaves, J.H., Vasconcelos, S.M., Nobre, H.V. Jr., Florenco de Sousa, F.C., Hyphantis, T.N., Carvalho, A.F., Macedo, D.S., Effects of doxycycline on depressive-like behavior in mice after lipopolysaccharide (LPS) administration. J. Psychiatr. Res. 47 (2013), 1521–1529.
64. Moreau, M., Andre, C., O'Connor, J.C., Dumich, S.A., Woods, J.A., Kelley, K.W., Dantzer, R., Lestage, J., Castanon, N., Inoculation of Bacillus Calmette-Guerin to mice induces an acute episode of sickness behavior followed by chronic depressive-like behavior. Brain Behav. Immun. 22 (2008), 1087–1095.
65. Munn, D.H., Sharma, M.D., Lee, J.R., Jhaver, K.G., Johnson, T.S., Keskin, D.B., Marshall, B., Chandler, P., Antonia, S.J., Burgess, R., Slingluff, C.L. Jr., Mellor, A.L., Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297 (2002), 1867–1870.
66. Murakami, Y., Hoshi, M., Imamura, Y., Arioka, Y., Yamamoto, Y., Saito, K., Remarkable role of indoleamine 2,3-dioxygenase and tryptophan metabolites in infectious diseases: potential role in macrophage-mediated inflammatory diseases. Mediators Inflamm., 2013, 2013, 391984.
67. Murakami, Y., Ishibashi, T., Tomita, E., Imamura, Y., Tashiro, T., Watcharanurak, K., Nishikawa, M., Takahashi, Y., Takakura, Y., Mitani, S., Fujigaki, H., Ohta, Y., Kubo, H., Mamiya, T., Nabeshima, T., Kim, H.C., Yamamoto, Y., Saito, K., Depressive symptoms as a side effect of Interferon-alpha therapy induced by induction of indoleamine 2,3-dioxygenase 1. Sci. Rep., 6, 2016, 29920.
68. Nikodemova, M., Watters, J.J., Efficient isolation of live microglia with preserved phenotypes from adult mouse brain. J. Neuroinflamm., 9, 2012, 147.
69. Obuchowicz, E., Bielecka, A.M., Paul-Samojedny, M., Pudelko, A., Kowalski, J., Imipramine and fluoxetine inhibit LPS-induced activation and affect morphology of microglial cells in the rat glial culture. Pharmacol. Rep. 66 (2014), 34–43.
70. O'Connor, J.C., Andre, C., Wang, Y., Lawson, M.A., Szegedi, S.S., Lestage, J., Castanon, N., Kelley, K.W., Dantzer, R., Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J. Neurosci. 29 (2009), 4200–4209.
71. O'Connor, J.C., Lawson, M.A., Andre, C., Briley, E.M., Szegedi, S.S., Lestage, J., Castanon, N., Herkenham, M., Dantzer, R., Kelley, K.W., Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J. Immunol. 182 (2009), 3202–3212.
72. O'Connor, J.C., Lawson, M.A., Andre, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K.W., Dantzer, R., Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 14 (2009), 511–522.
73. O'Leary, O.F., Bechtholt, A.J., Crowley, J.J., Hill, T.E., Page, M.E., Lucki, I., Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test. Psychopharmacology 192 (2007), 357–371.
74. Pan, W., Banks, W.A., Kastin, A.J., Permeability of the blood-brain and blood-spinal cord barriers to interferons. J. Neuroimmunol. 76 (1997), 105–111.
75. Park, S.E., Dantzer, R., Kelley, K.W., McCusker, R.H., Central administration of insulin-like growth factor-I decreases depressive-like behavior and brain cytokine expression in mice. J. Neuroinflamm., 8, 2011, 12.
76. Platt, B., Schulenberg, J., Klee, N., Nizami, M., Clark, J.A., A depressive phenotype induced by Bacille Calmette Guerin in ‘susceptible’ animals: sensitivity to antidepressants. Psychopharmacology 226 (2013), 501–513.
77. Raison, C.L., The promise and limitations of anti-inflammatory agents for the treatment of major depressive disorder. Curr. Top. Behav. Neurosci. 31 (2017), 287–302.
78. Raison, C.L., Miller, A.H., Is depression an inflammatory disorder?. Curr. Psychiatry Rep. 13 (2011), 467–475.
79. Raison, C.L., Borisov, A.S., Majer, M., Drake, D.F., Pagnoni, G., Woolwine, B.J., Vogt, G.J., Massung, B., Miller, A.H., Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol. Psychiatry 65 (2009), 296–303.
80. Raison, C.L., Dantzer, R., Kelley, K.W., Lawson, M.A., Woolwine, B.J., Vogt, G., Spivey, J.R., Saito, K., Miller, A.H., CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol. Psychiatry 15 (2010), 393–403.
81. Reichenberg, A., Yirmiya, R., Schuld, A., Kraus, T., Haack, M., Morag, A., Pollmacher, T., Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 58 (2001), 445–452.
82. Rink, L., Plümäkers, B., Sheldrick, A.J., Fulda, S., Himmerich, H., IFN-γ reduction by tricyclic antidepressants. Int J Psychiatry Med 40 (2010), 413–424.
83. Salazar, A., Gonzalez-Rivera, B.L., Redus, L., Parrott, J.M., O'Connor, J.C., Indoleamine 2,3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge. Horm. Behav. 62 (2012), 202–209.
84. Sanacora, G., Banasr, M., From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biol. Psychiatry 73 (2013), 1172–1179.
85. Shen, Y., Connor, T.J., Nolan, Y., Kelly, J.P., Leonard, B.E., Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Sci. 65 (1999), 1773–1786.
86. Stancic, M., van Horssen, J., Thijssen, V.L., Gabius, H.J., van der Valk, P., Hoekstra, D., Baron, W., Increased expression of distinct galectins in multiple sclerosis lesions. Neuropathol. Appl. Neurobiol. 37 (2011), 654–671.
87. Steiner, J., Walter, M., Gos, T., Guillemin, G.J., Bernstein, H.G., Sarnyai, Z., Mawrin, C., Brisch, R., Bielau, H., Meyer zu Schwabedissen, L., Bogerts, B., Myint, A.M., Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?. J. Neuroinflamm., 8, 2011, 94.
88. Stinnett, G.S., Westphal, N.J., Seasholtz, A.F., Pituitary CRH-binding protein and stress in female mice. Physiol. Behav. 150 (2015), 16–23.
89. Su, F., Yi, H., Xu, L., Zhang, Z., Fluoxetine and S-citalopram inhibit M1 activation and promote M2 activation of microglia in vitro. Neuroscience 294 (2015), 60–68.
90. Sulakhiya, K., Keshavlal, G.P., Bezbaruah, B.B., Dwivedi, S., Gurjar, S.S., Munde, N., Jangra, A., Lahkar, M., Gogoi, R., Lipopolysaccharide induced anxiety- and depressive-like behaviour in mice are prevented by chronic pre-treatment of esculetin. Neurosci. Lett. 611 (2016), 106–111.
91. Tattevin, P., Monnier, D., Tribut, O., Dulong, J., Bescher, N., Mourcin, F., Uhel, F., Le Tulzo, Y., Tarte, K., Enhanced indoleamine 2,3-dioxygenase activity in patients with severe sepsis and septic shock. J. Infect. Dis. 201 (2010), 956–966.
92. Tomaz, V.S., Cordeiro, R.C., Costa, A.M., de Lucena, D.F., Nobre Junior, H.V., de Sousa, F.C., Vasconcelos, S.M., Vale, M.L., Quevedo, J., Macedo, D., Antidepressant-like effect of nitric oxide synthase inhibitors and sildenafil against lipopolysaccharide-induced depressive-like behavior in mice. Neuroscience 268 (2014), 236–246.
93. Vijaya Kumar, K., Rudra, A., Sreedhara, M.V., Siva Subramani, T., Prasad, D.S., Das, M.L., Murugesan, S., Yadav, R., Trivedi, R.K., Louis, J.V., Li, Y.W., Bristow, L.J., Naidu, P.S., Vikramadithyan, R.K., Bacillus Calmette-Guerin vaccine induces a selective serotonin reuptake inhibitor (SSRI)-resistant depression like phenotype in mice. Brain Behav. Immun. 42 (2014), 204–211.
94. Wang, N., Yu, H.Y., Shen, X.F., Gao, Z.Q., Yang, C., Yang, J.J., Zhang, G.F., The rapid antidepressant effect of ketamine in rats is associated with down-regulation of pro-inflammatory cytokines in the hippocampus. Ups. J. Med. Sci. 120 (2015), 241–248.
95. Wang, X., Zhang, S., Lin, F., Chu, W., Yue, S., Elevated galectin-3 levels in the serum of patients with Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen. 30 (2015), 729–732.
96. WHO, 2011. World Health Organization: Global burden of mental disorders and the need for a comprehensive, coordinated response from health and social sectors at the country level. In: Secretariat (Ed.), Executive Board Meeting, EB130/9 130th session, Provisional agenda item 6.2 World Health Organization, pp. 1–6.
97. Yirmiya, R., Rimmerman, N., Reshef, R., Depression as a microglial disease. Trends Neurosci. 38 (2015), 637–658.